Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy. Drug therapies directed against the epidermal growth factor pathway and related molecular targets play an increasingly important role in cancer therapy and represent the majority of oncology therapies in development, but do not provide benefit for all patients.
“The granting of this patent recognizes our unique approach and innovation in this exciting area of molecular diagnostics”
The patent also covers mass-spectrometry processes, algorithms and other important aspects of the Company's core technology, ProTS®, and represents the cornerstone of the Company's growing intellectual property portfolio.
"The granting of this patent recognizes our unique approach and innovation in this exciting area of molecular diagnostics," commented David Brunel, Biodesix CEO. "We are committed to applying our technology to develop clinically meaningful tests that enhance clinical decision making and patient care."
Study links air pollution to increased colorectal cancer risk through DNA changes